Enhanced capability for molecular diagnostic system

July 2013—Abbott has introduced a new capability for its RealTime m2000 system to enhance the system’s flexibility and make molecular testing easier and more efficient. Abbott’s mPlus makes it possible for laboratories to perform molecular diagnostic tests for infectious disease detection and therapy monitoring.

mPlus capability is available for Abbott’s RealTime HIV, HCV, HBV, CT/NG, and CT assays outside the United States and for the RealTime CT/NG assay in the United States.

Abbott’s mPlus will allow laboratories to process samples when they are ready rather than holding them for larger batch runs, providing faster results more quickly. mPlus capability will also optimize reagent use, reduce the cost of laboratory operations, and offer an automatic inventory feature to improve system use.

Abbott, 224-361-7966